A scientific overview of the most prevalent bacterial cause of foodborne illness in the developed world and its primary vehicle — broiler poultry.
Public Health Advisory: Campylobacteriosis is a notifiable disease in the UK and EU. Cases have risen consecutively for 11 of the last 12 years. Poultry remains the attributable source in an estimated 50–80% of human cases.
Pathogen Profile
Campylobacter is a genus of gram-negative, microaerophilic, spiral-shaped bacteria. Two species — C. jejuni and C. coli — account for over 95% of human clinical infections, with C. jejuni responsible for approximately 85% of cases.
The organism is a commensal coloniser of the intestinal tract of broiler chickens, typically present at 10⁶–10⁸ CFU/g in caecal contents. During slaughter and processing, caecal contamination of the carcass surface is the primary mechanism by which the pathogen enters the food chain.
Unlike many foodborne pathogens, Campylobacter has an extremely low infectious dose in humans — as few as 500 organisms are sufficient to cause clinical illness in a susceptible individual.
Clinical Impact
Campylobacteriosis ranges from mild self-limiting gastroenteritis to life-threatening systemic complications. Vulnerable populations face disproportionately severe outcomes.
Onset 2–5 days post-ingestion. Symptoms include profuse watery or bloody diarrhoea, severe abdominal cramping, fever (38–40°C), nausea, and vomiting. Duration typically 3–7 days. Hospitalisation required in approximately 15% of confirmed cases.
Approximately 1 in 1,000 Campylobacter cases triggers Guillain–Barré Syndrome (GBS) — an acute post-infectious autoimmune polyneuropathy. Campylobacter is the single most common identifiable antecedent infection in GBS globally, accounting for up to 30% of all GBS cases. Partial or complete paralysis can be permanent.
Post-infectious reactive arthritis (ReA) develops in 1–5% of Campylobacter patients, typically 1–3 weeks after initial illness. Joint inflammation, particularly in large joints (knees, ankles), may persist for months to years. HLA-B27-positive individuals are at greatest risk.
Immunocompromised individuals, pregnant women (risk of foetal loss), neonates, and the elderly (≥65 years) face significantly elevated mortality risk. Bacteraemia — bloodstream invasion — occurs in approximately 1% of cases and carries a case fatality rate of 15–30%.
Fluoroquinolone-resistant Campylobacter (ciprofloxacin MIC ≥ 4 mg/L) now accounts for over 47% of UK clinical isolates (PHE, 2023). Macrolide (azithromycin) resistance is emerging at 4.3%. Resistant infections result in longer illness duration, higher hospitalisation rates, and reduced treatment options. The WHO classifies Campylobacter as a High Priority pathogen on its Global Priority Pathogens List.
Contamination Data
Regulatory surveillance programmes across the UK and EU consistently document high prevalence and elevated counts of Campylobacter on retail and wholesale poultry.
| Contamination Level | % Samples (2023) | % Samples (2021) | Trend |
|---|---|---|---|
| Not detected | 26.6% | 29.2% | ↓ Worsening |
| <100 CFU/g (low) | 25.9% | 27.1% | → Stable |
| 100–999 CFU/g (moderate) | 28.3% | 24.8% | ↑ Increasing |
| >1,000 CFU/g (high risk) | 19.2% | 18.9% | ↑ Increasing |
Source: UK FSA Campylobacter Retail Chicken Survey, 2021 & 2023. n≥1,000 samples per survey period.
% of samples with >1,000 CFU/g (neck-skin). Processing stage estimates from published literature; retail figure from UK FSA Survey 2023; Duplex™ retail figure from UltraBiotecs CRO trial (2024).
EU-Wide Surveillance
| Country | Broiler Flock Prevalence | Retail Chicken Prevalence | Human Incidence (per 100k) | Risk Category |
|---|---|---|---|---|
| United Kingdom | 51.4% | 73.4% | 103.2 | Very High |
| Czech Republic | 66.2% | 68.1% | 207.4 | Very High |
| Luxembourg | 59.3% | 62.7% | 195.3 | Very High |
| Germany | 48.7% | 57.2% | 88.4 | High |
| Netherlands | 44.1% | 53.6% | 79.6 | High |
| France | 39.2% | 48.9% | 57.1 | Moderate–High |
| Spain | 32.6% | 41.3% | 43.2 | Moderate |
| Finland | 3.2% | 8.7% | 22.4 | Low |
Source: EFSA/ECDC Joint Zoonoses Report 2023. Human incidence based on confirmed laboratory cases; true incidence estimated at 10–20× reported.
Regulatory Framework
EU Regulation (EC) 2073/2005 on microbiological criteria for foodstuffs sets mandatory process hygiene criteria (PHC) for Campylobacter on broiler carcasses.
| Stage | Acceptable (m) | Marginal (M) | Action Required |
|---|---|---|---|
| Post-chilling neck-skin | <1,000 CFU/g | 1,000–10,000 CFU/g | Process review |
| Abattoir process check | <1,000 CFU/cm² | >1,000 CFU/cm² | Immediate HACCP review |
Per Regulation (EC) 2073/2005 Annex I Chapter 2. PHC apply at the point of control, not retail.
The UK has retained the EC 2073/2005 PHC thresholds under the UK Food Safety and Hygiene (England) Regulations 2013. The FSA has additionally proposed industry-specific targets: <1,000 CFU/g on ≥95% of carcasses by 2027 under the Campylobacter Reduction Programme. Non-compliance can trigger voluntary recall and enforcement action under the Food Safety Act 1990.
The Solution
Duplex™ achieves >6 log₁₀ reduction in Campylobacter jejuni and C. coli on broiler neck-skin — the single highest-impact intervention available in modern poultry processing. At this reduction level, even heavily contaminated carcasses (10⁵ CFU/cm²) are brought well below the regulatory PHC threshold.
View Duplex™ Efficacy Data → Request a Plant Assessment